Jan. 12 at 9:19 PM
Raymond James reiterated
$COGT Strong Buy-
$60, and provided its WW product revenue ests for bezuclasinib in 3 indications for FY27-30, w/ 1 NDA submitted & 2 on deck in 1H26, ahead of competitors conference this week.
$SNY - BPMC
$NVS $OPHLY GSK
$CLDX
Raymond James said in its note, Recall, Cogent submitted an NDA for NonAdvSM in December based on positive SUMMIT data presented earlier last year and
expects FDA to accept the NDA by the end of February 2026.
Moreover, Cogent is on track to submit two more NDAs for GIST and AdvSM in April 2026 and 1H26, respectively.
Overall, by Cogent's estimates and our model, bezuclastinib's commercialization is on deck in 2H26 in all three indications,
and we model total WW product revenues of
$393.4M,
$773.6M,
$1.35B, and
$1.83B for FY27-
30, respectively.
